MediWound Secures $3.3M DoW Boost for Battlefield Burn Treatment…

Event summary

MediWound received an additional $3.3M from the U.S. Department of War, bringing total program funding to $21.8M.
Funding supports development of a room-temperature-stable formulation of NexoBrid for battlefield burn care.
Program aims to advance through Investigational New Drug (IND) submission to the FDA.
Development is part of MediWound’s existing North American license agreement with Vericel Corporation.

The big picture

The additional funding underscores the strategic importance of battlefield-ready medical solutions, particularly in environments with limited access to surgical capabilities and cold-chain infrastructure. MediWound’s focus on a room-temperature-stable formulation of NexoBrid aligns with broader industry trends toward enhancing the portability and usability of medical treatments in austere settings. The collaboration with Vericel further solidifies NexoBrid’s position as a key player in the burn care market.

What we're watching

Regulatory Milestones: The pace at which MediWound advances toward IND submission will determine the timeline for clinical validation.
Commercialization Strategy: Whether Vericel can effectively leverage its exclusive rights to NexoBrid in North America to drive market adoption.
Operational Execution: How MediWound’s ability to establish in-house cGMP manufacturing capabilities will impact development timelines.